Niagen Bioscience Inc. Common Stock (NAGE)

FairStock Score: 49/100 — MIXED

Key Financials

Strengths

• Generates $5 million in annual free cash flow (1.3% yield on market cap)
• High return on equity of 28.4% demonstrating efficient capital deployment
• Conservative balance sheet with debt-to-equity of just 0.04, providing financial flexibility
• Altman Z-Score of 6.8 confirms minimal bankruptcy risk and strong solvency
• Revenue growth of 16.2% demonstrates strong top-line momentum

Concerns

• Trades significantly above Graham Number ($2) with negative 129% margin of safety—limited downside protection

AI Analysis

Niagen Bioscience Inc. Common Stock is a micro-cap healthcare company valued at $382 million. The business generates $129 million in annual revenue with a 3.2% net margin and $5 million in free cash flow. From a quality standpoint, Niagen shows Altman Z-Score of 6.8 confirms fortress-level solvency and strong 28% ROE. On valuation, the stock is reasonably priced at 23.6x earnings, with trades far above its Graham Number ($2) with no margin of safety. Growth dynamics show revenue growing at 16.2% and profit growth of -42.4%. Our composite FairStock Score of 49/100 reflects mixed fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

Niagen's 16% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. With $5 million in annual free cash flow (1.3% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer